EndGenitor Technologies, Inc

Developing Novel Adult Stem Cell Products For Regenerative Medicine™


 EndGenitor is committed to developing therapies for patents with a variety of life threatening illnesses, by discovering and harnessing the exciting potential of isolated adult stem /progenitor cells obtained from umbilical cord blood. Priority areas of work include cell therapies which may create new blood vessels in heart attack patients, cell therapies targeted toward preventing serious injury in acute renal failure patients, and a cell based antitumor therapy.



“Developing novel adult stem cell  products for regenerative medicine”

EndGenitor is using cord blood derived cells  to develop proprietary novel stem cell therapeutic products for the treatment of debilitating chronic degenerative diseases. 


About Us



Related Publications

Contact Us